Pacira BioSciences, Inc. [PCRX] - Pacira BioSciences / Viatris merger
Viatris Inc. has entered into a definitive merger agreement to acquire Pacira BioSciences, Inc. for $36.50 per share in cash, with the tender offer expected to commence within 15 business days.
Why this matters
Pacira BioSciences, Inc., a Delaware-incorporated company in the pharmaceutical preparations industry, specializes in developing and commercializing non-opioid pain management and regenerative health solutions. Viatris Inc. has entered into a definitive merger agreement to acquire Pacira for $36.50 per share in cash. This acquisition follows a strategic review and is expected to involve costs related to severance, employee benefits, and other operational consolidations. The tender offer for Pacira's outstanding shares is anticipated to commence within 15 business days.